Open access
Open access
Powered by Google Translator Translator

All Posts

Current perioperative care in pancreatoduodenectomy: a step-by-step surgical roadmap from first visit to discharge

16 May, 2023 | 14:52h | UTC

Current Perioperative Care in Pancreatoduodenectomy: A Step-by-Step Surgical Roadmap from First Visit to Discharge – Cancers

 

Commentary on Twitter

 

M-A | Evaluation of the effectiveness of telehealth chronic disease management system

16 May, 2023 | 14:55h | UTC

Evaluation of the Effectiveness of Telehealth Chronic Disease Management System: Systematic Review and Meta-analysis – Journal of Medical Internet Research

 

Consensus Paper | Evidence-based consensus guidelines for the management of catatonia

16 May, 2023 | 14:50h | UTC

Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology – Journal of Psychopharmacology

 

Commentary from the author on Twitter (thread – click for more)

 

RCT | Optimizing the timing of whooping cough immunization in mums through investigating pertussis vaccination in pregnancy

16 May, 2023 | 14:49h | UTC

Optimising the timing of whooping cough immunisation in mums (OpTIMUM) through investigating pertussis vaccination in pregnancy: an open-label, equivalence, randomised controlled trial – Microbiome

 

RCT | Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma

16 May, 2023 | 14:48h | UTC

Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial – Nature Medicine

News Release: Investigational drug may improve stem cell transplantation for multiple myeloma patients – Washington University in St. Louis

 

Commentary on Twitter

 

Consensus Paper | Diagnosis and antimicrobial treatment for infections post-ACL reconstruction

16 May, 2023 | 14:46h | UTC

Recommendations on diagnosis and antimicrobial treatment of infections after anterior cruciate ligament reconstruction (ACL-R) endorsed by ESSKA and EBJIS – Journal of Infection

 

M-A | Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome?

16 May, 2023 | 14:44h | UTC

Is it necessary to wear compression stockings and how long should they be worn for preventing post thrombotic syndrome? A meta-analysis of randomized controlled trials – Thrombosis Research

 

RCT | Colchicine ineffective for pain relief in hand osteoarthritis patients

16 May, 2023 | 14:42h | UTC

Colchicine twice a day for hand osteoarthritis (COLOR): a double-blind, randomised, placebo-controlled trial – The Lancet Rheumatology (link to abstract – $ for full-text)

Commentary: Colchicine Does Not Relieve OA-Related Hand Pain Compared With Placebo – DocWireNews

 

Commentary on Twitter

 

Cohort Study | 5-mm margins may be adequate for T1a melanoma excision near critical structures

16 May, 2023 | 14:40h | UTC

Association of Excision Margin Size With Local Recurrence and Survival in Patients With T1a Melanoma at Critical Structures – JAMA Dermatology (link to abstract – $ for full-text)

Commentary: Melanoma Excisions with 5 Millimeter Margins Linked to Less Risk of Local Recurrence – HCP Live

 

Commentary on Twitter

 

Stent angioplasty in coronary artery anomalies with intramural course: when, why, how, with what results?

16 May, 2023 | 14:38h | UTC

Stent Angioplasty in Coronary Artery Anomalies With Intramural Course: When, Why, How, With What Results? – Journal of the Society for Cardiovascular Angiography & Interventions

 

Commentary on Twitter

 

Towards precision pain medicine for pain after cancer: guidelines for pain phenotyping using nociplastic pain criteria

16 May, 2023 | 14:35h | UTC

Towards precision pain medicine for pain after cancer: the Cancer Pain Phenotyping Network multidisciplinary international guidelines for pain phenotyping using nociplastic pain criteria – British Journal of Anaesthesia

 

Commentary on Twitter

Article under a Creative Commons (CC BY-NC-ND 4.0) license

 

RCT | Per-oral endoscopic myotomy outperforms pneumatic dilation for post-laparoscopic heller myotomy achalasia

16 May, 2023 | 14:36h | UTC

The Efficacy of Peroral Endoscopic Myotomy vs Pneumatic Dilation as Treatment for Patients With Achalasia Suffering From Persistent or Recurrent Symptoms After Laparoscopic Heller Myotomy: A Randomized Clinical Trial – Gastroenterology

 

The impact of hyperhidrosis on quality of life: a review of the literature

16 May, 2023 | 14:33h | UTC

The Impact of Hyperhidrosis on Quality of Life: A Review of the Literature – American Journal of Clinical Dermatology

 

M-A | Medial–lateral versus lateral-only pinning fixation in children with displaced supracondylar humeral fractures

16 May, 2023 | 14:32h | UTC

Medial–lateral versus lateral-only pinning fixation in children with displaced supracondylar humeral fractures: a meta-analysis of randomized controlled trials – Journal of Orthopaedic Surgery and Research

 

RCT | Gefitinib plus chemotherapy vs. Gefitinib alone in untreated EGFR-mutant NSCLC with brain metastases

16 May, 2023 | 14:30h | UTC

Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non–Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study – JAMA Network Open

 

Commentary on Twitter

 

Clinical Trial Update | Pembrolizumab plus chemotherapy in squamous non–small-cell lung cancer

16 May, 2023 | 14:25h | UTC

Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer: 5-Year Update of the Phase III KEYNOTE-407 Study – Journal of Clinical Oncology

Commentaries:

At 5-Year Follow-Up, Benefits of Pembrolizumab on Clinical Outcomes in Squamous NSCLC Maintained – ASCO Daily News

Addition of Pembrolizumab to Chemotherapy in First-Line Treatment of Metastatic Squamous NSCLC: 5-Year Update of KEYNOTE-407 – The ASCO Post

Original Study: Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer – New England Journal of Medicine

 

RCT | Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia

16 May, 2023 | 14:24h | UTC

Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström’s Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström’s Macroglobulinemia – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentary: Addition of Bortezomib to First-Line Dexamethasone, Rituximab, and Cyclophosphamide for Waldenström’s Macroglobulinemia – The ASCO Post

 

RCT | Interrupted vs. continuous suture technique for biliary-enteric anastomosis

16 May, 2023 | 14:22h | UTC

Interrupted versus continuous suture technique for biliary-enteric anastomosis: randomized clinical trial – BJS Open

 

Commentary on Twitter

 

Practice Guidance | Differential diagnosis of suspected COPD exacerbations in the acute care setting

15 May, 2023 | 13:26h | UTC

Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice – American Journal of Respiratory and Critical Care Medicine

 

Commentary on Twitter

 

Canadian Task Force advises fragility fracture screening for women over 65, but not for men or younger women

15 May, 2023 | 13:23h | UTC

Recommendations on screening for primary prevention of fragility fractures – Canadian Medical Association Journal

Related USPSTF Statement: Screening Osteoporosis to Prevent Fractures

 

Guideline | Acute dizziness and vertigo in the emergency department

15 May, 2023 | 13:25h | UTC

Guidelines for reasonable and appropriate care in the emergency department 3 (GRACE-3): Acute dizziness and vertigo in the emergency department – Academic Emergency Medicine

News Release: New guideline for treatment of acute dizziness and vertigo in the emergency department – Society for Academic Emergency Medicine

 

RCT | Rivaroxaban doesn’t reduce thrombotic events, hospitalization, or death in outpatients with COVID-19

15 May, 2023 | 13:19h | UTC

Summary: The PREVENT-HD trial, a double-blind, placebo-controlled randomized study, was conducted to evaluate the effectiveness of prophylactic anticoagulation in reducing venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor. The trial took place between August 2020 and April 2022 across 14 US integrated healthcare delivery networks, with 1,284 patients enrolled and randomly assigned to receive either 10 mg of oral rivaroxaban or placebo daily for 35 days.

However, the study was terminated prematurely due to enrollment challenges and lower-than-expected event rates. The primary efficacy outcome, a composite of various hazardous events, occurred in 3.4% of the rivaroxaban group and 3.0% of the placebo group, with no significant difference between the two groups (hazard ratio, 1.16 [95% CI, 0.63–2.15]; P=0.63). No critical-site or fatal bleeding was observed, and only one patient in the rivaroxaban group experienced a major bleed.

In conclusion, rivaroxaban prescribed for 35 days in nonhospitalized patients with symptomatic COVID-19 at risk for thrombosis does not appear to reduce the composite end point of venous and arterial thrombotic events, hospitalization, and death. The study’s premature termination and lower-than-expected event rates may limit the generalizability of these findings.

Article: Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial – Circulation

 

Commentary on Twitter

 

RCT | Prophylactic antibiotics show no statistically significant survival improvement in severe alcohol-related hepatitis

15 May, 2023 | 13:21h | UTC

Summary: This multicenter, randomized, double-blind clinical trial aimed to determine the efficacy of amoxicillin-clavulanate combined with prednisolone compared to placebo combined with prednisolone on mortality in patients hospitalized with severe alcohol-related hepatitis. The study involved 284 patients from 25 centers in France and Belgium with biopsy-proven severe alcohol-related hepatitis, who were followed up for 180 days.

The primary outcome was all-cause mortality at 60 days, while secondary outcomes included mortality at 90 and 180 days, infection rates, hepatorenal syndrome, and changes in Model for End-stage Liver Disease (MELD) and Lille scores. The results showed no statistically significant difference in 60-day mortality between the two groups, with 17.3% in the amoxicillin-clavulanate group and 21.3% in the placebo group. However, infection rates at 60 days were significantly lower in the amoxicillin-clavulanate group compared to the placebo group.

It is worth noting that the study may have been underpowered, as the absolute risk difference of 4% did not achieve statistical significance. In conclusion, the combination of amoxicillin-clavulanate and prednisolone did not show a statistically significant improvement in 2-month survival in patients hospitalized with severe alcohol-related hepatitis compared to prednisolone alone. These findings do not support the use of prophylactic antibiotics to improve survival in this patient population, but the potential underpowered nature of the study should be considered.

Article: Effect of Prophylactic Antibiotics on Mortality in Severe Alcohol-Related Hepatitis: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)

 

Commentary on Twitter

 

RCT | Cognitive behavioral therapy proves effective for severe post-COVID-19 fatigue

15 May, 2023 | 13:16h | UTC

Efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19: results of a randomized controlled trial – Clinical Infectious Diseases

News Release: Cognitive behavioral therapy lessens post-viral fatigue after COVID-19 – Amsterdam UMC

 

Commentary on Twitter

 

Therapeutic plasma exchange: Core curriculum 2023

15 May, 2023 | 13:14h | UTC

Therapeutic Plasma Exchange: Core Curriculum 2023 – American Journal of Kidney Diseases

 

Commentary on Twitter

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.